HEMOLYTIC ANEMIA: GENETIC INSIGHTS AND NEW THERAPEUTIC AVENUES

Abstract

Hemolytic anemia represents a heterogeneous group of disorders characterized by the premature destruction of red blood cells (RBCs), leading to anemia and associated clinical manifestations. Over recent years, significant strides have been made in unraveling the genetic basis of hemolytic anemias, providing valuable insights into the underlying molecular mechanisms and paving the way for the development of novel therapeutic strategies. This paper provides a comprehensive review of the genetic insights into hemolytic anemias and explores emerging therapeutic avenues, including targeted molecular therapies, immunomodulatory approaches, gene therapy, and bone marrow transplantation. The potential applications of these innovative therapeutic modalities in the management of various genetic forms of hemolytic anemias are discussed, highlighting the promise of personalized medicine in improving outcomes for affected individuals.